Spanish pharmaceutical company Almirall has entered an agreement to acquire Allergan’s Medical Dermatology Unit US portfolio, consisting of five brands for acne and dermatoses treatment.
The brands acquired include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (fludroxycortide), as well as Seysara (sarecycline), a new tetracycline-derived antibiotic with anti-inflammatory qualities for treating moderate to severe acne. FDA approval of Seysara (sarecycline) is anticipated in quarter four of this year.
All products will be distributed through Almirall’s US team, which the company claims has thorough knowledge of the oral acne market and Allergan’s portfolio.
Peter Guenter, chief executive officer at Almirall, noted, “This is a transformational deal for Almirall. It will reinforce and consolidate our position in the world’s largest dermatology market and is a well-balanced portfolio of mature and growth brands with a major launch opportunity of an innovative New Chemical Entity (NCE).”
He continued, “It is perfectly complementary to our existing platform and will be immediately accretive to our earnings. It offers us medium to long term top and bottom line growth opportunities.”
The deal, which is conditional to the clearance by the relevant authorities, is expected to close in the final quarter of this year.